ArticleBMC public health2025
The global, regional, and National burden of parkinson's disease in 204 countries and territories, 1990-2021: a systematic analysis for the global burden of disease study 2021.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Deep brain stimulation targeting the subthalamic nucleus versus the globus pallidus internus for tremor control in parkinson's disease: A systematic review and meta analysis.Neurosurgical review · 2025Pooled it
- Pathogenesis-Driven Drug Repurposing with a Self-Nanoemulsifying Delivery System for Parkinson's Disease.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Astrocytic HSP90AA1 Upregulation and Altered Synaptic Signaling in Parkinson's Disease: Transcriptomic Screening and In Vivo Validation.International journal of molecular sciences · 2026Article
- Pharmacological mechanisms of fisetin in neurodegenerative disorders: regulation of neuroinflammatory, oxidative, and autophagic pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Reframing welders' parkinsonism: from the "idiopathic" label to biological causation and legal recognition.Annals of occupational and environmental medicine · 2026Review
- Mapping the Parkinson's pandemic: Unveiling and addressing the global burden.Journal of Parkinson's disease · 2026Review
- Iron accumulation in the substantia nigra is linked to functional network connectivity alterations in early-stage Parkinson's Disease: an exploratory study.NPJ Parkinson's disease · 2026Article
- Dose-Dependent Neuroprotective Effects of Valproate on Motor Function and Striatal D2 Receptor Stability in a 6-OHDA Rat Model of Parkinson's Disease.International journal of molecular sciences · 2026Article
- Deep Brain Stimulation as a Rehabilitation Amplifier: A Precision-Oriented, Network-Guided Framework for Functional Restoration in Movement Disorders.Journal of clinical medicine · 2026Review
- Epigenetic Dysregulation in Neurodegeneration: The Role of Histone Deacetylases and Emerging Inhibitor Strategies.Biomolecules · 2026Review
- Dynamic structural profiling of PINK1 mutations (T313M and L347P) reveals a vital molecular perturbation namely phospho-Serine 65 ubiquitin recognition point in mitophagy mediated autosomal recessive Parkinson's disease (ARPD).Frontiers in molecular neuroscience · 2026Article
- Discovery of Sennoside A as a NaturalResearch (Washington, D.C.) · 2026Article
- MiR-7 in neurological disorders: beyond metabolic dysregulation.Frontiers in neuroscience · 2026Review
- Sphingolipid-Neuroinflammation Axis in Parkinson's Disease: Focus on S1P/SPHK1-NF‑κB Signaling.Journal of inflammation research · 2026Review
- Speed-Variable Treadmill Training Improves Hand Motor Function in Individuals With Parkinson's Disease.Parkinson's disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundParkinson's disease (PD) represents a prevalent neurodegenerative condition that leads to significant disability and contributes to a growing public health challenge worldwide. However, a comprehensive report on progress from 1990 to 2021 is still lacking, especially regarding the risk factors associated with PD by gender and age. This study aims to examine the patterns of PD incidence, mortality rates, and disability-adjusted life years (DALYs) across all age groups, along with the risk factors linked to PD-related fatalities, spanning the years from 1990 to 2021.
methodsWe retrieved data on PD from the Global Burden of Disease Study 2021. The burden of PD was assessed using incidence, deaths, and DALYs, with corresponding 95% uncertainty interval (UI). Analyses were conducted globally, regionally, and nationally for the period between 1990 and 2021, stratified by age, sex, and the Socio-demographic Index (SDI). Estimated annual percentage changes (EAPCs) were calculated to assess temporal trends. Only cases directly attributable to PD were included, and a comorbidity correction was applied to ensure accurate estimation of the burden.
resultsIn 2021, there were 13.35 million (95% UI: 12.67-14.08) incident cases and 388,194 (95% UI: 347,250-417,388) deaths cases globally. The global DALYs attributed to PD climbed from 53.51 to 94.68 per 100,000 population (95% UI: 49.54-57.56 to 85.37-103.11) from 1990 to 2021. During the same period, age-standardized incidence rates rose from 7.82 to 16.92 per 100,000 population (95% UI: 6.95-8.75 to 15.16-18.82), while mortality rates increased from 2.78 to 4.91 per 100,000 population (95% UI: 2.55-2.97 to 4.40-5.29). Among the five SDI regions, the high SDI region reported the highest PD mortality rate in 2021. The burden of PD was most pronounced in the 85-89 age group. Smoking was identified as a key risk factor for PD-associated mortality in 2021, with the proportion of deaths attributable to smoking ranging from - 9.09% in individuals aged 50-54 years to -2.69% in those aged 95 years and older.
conclusionsPD represents a significant and escalating global health challenge, driven by increasing incidence rates and an aging population. This growing burden highlights the urgent need for effective strategies in prevention, early diagnosis, and tailored management, particularly for elderly males who are disproportionately affected. Addressing modifiable risk factors and advancing etiological research are crucial to mitigating the rising prevalence and optimizing resource allocation. Coordinated public health interventions and robust healthcare policies are essential to reduce the global impact of PD and improve outcomes for affected individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.